CIK in Treating Patients With Bladder Cancer

Status Active, not recruiting

Clinical Trial Summary

Chemotherapy is the main treatment method for patients with Bladder Cancer. However, Relapse remains the major cause of treatment failure.Biological therapies such as CIK stimulate the immune system and stop tumor cells from growing. A series of studies reported that cytokine-induced killer cells (CIK) have a broad anti-tumor spectrum. The investigators suppose that CIK will improve the prognosis. Combining chemotherapy with biological therapy may kill more tumor cells. In this study, the patients will be treated with CIK cells after chemotherapy. The purpose of this study is to evaluate the efficacy of CIK for Bladder Cancer.

Clinical Trial Description

About 1500 patients with staging I-III of Bladder Cancer, after accepting chemotherapy, will be randomly divided into group A (receive CIK treatment) or group B (just regularly follow up), and the randomize ratio will be 1:1. Patients in group A will receive 3 cycles of CIK cells treatment (every 12 weeks). Patients in group B will have no anti-tumor therapy. ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Urinary Bladder Neoplasms

Clinical Trial Details

NCT number	NCT02489890
Study type	Interventional
Source	The First People's Hospital of Changzhou
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	February 2016
Completion date	July 2030

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02612194` - LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer	Phase 2
Active, not recruiting	`NCT02805608` - uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer	Phase 2
Not yet recruiting	`NCT02534623` - Postoperative Quality of Recovery After Transurethral Resection of the Bladder	N/A
Recruiting	`NCT02228473` - Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort	N/A
Completed	`NCT02778243` - Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level	N/A
Recruiting	`NCT05007106` - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)	Phase 2
Completed	`NCT01688999` - Cabozantinib for Advanced Urothelial Cancer	Phase 2
Completed	`NCT03219333` - A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer	Phase 2
Recruiting	`NCT05068180` - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients	Phase 4
Terminated	`NCT02560038` - Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer	Phase 2
Not yet recruiting	`NCT02252445` - Propofol and Sevoflurane for Catheter-Related Bladder Discomfort	N/A
Not yet recruiting	`NCT02760953` - TURBt With Adjuvant Cryoablation to Treat Bladder Cancer	N/A
Terminated	`NCT04430036` - AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer	Phase 2
Active, not recruiting	`NCT06289283` - Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder
Active, not recruiting	`NCT03288545` - A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03661320` - A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer	Phase 3
Completed	`NCT01478685` - A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors	Phase 1
Completed	`NCT03404791` - A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy	Phase 1
Terminated	`NCT01479348` - Imaging Study for FdCyd and THU Cancer Treatment	Early Phase 1
Recruiting	`NCT05742867` - A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder